INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
Study sponsor: InMed Pharmaceuticals Inc. · INM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-04-03Actual
Enrollment · participants19Actual
Source updated2023-07-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.